Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP341 in advanced solid tumors
NCT05631327Phase 1Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2022
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of JZP341 in solid tumor (advanced stage) and colorectal adenocarcinoma (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Dose-Limiting Toxicities at Day 28, Treatment-emergent Adverse Events at 5 years and 8 more. Started Dec 2022; status: terminated.
02
Drugs
JZP341
03
Conditions
solid tumor (advanced stage)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT05631327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631327.